New HIV remission strategy combines vaccine, antibody, and drug – but trial pulled before start
NCT ID NCT03619278
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study aimed to see if a personalized RNA vaccine, a powerful antibody (10-1074), and a drug called romidepsin could help people with HIV stop their daily antiretroviral pills while keeping the virus under control. The trial planned to enroll 56 adults with well-controlled HIV. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized RNA vaccine (HIVACAR01), broadly neutralizing antibody (10-1074), and romidepsin
What this could lead to
If successful, this approach could allow people with HIV to stop daily antiretroviral therapy and maintain undetectable viral levels, pointing toward a functional cure.
What could go wrong
This trial was withdrawn before enrolling any participants, so no data exist. The combination therapy may cause severe side effects or fail to control the virus, and participants would still need lifelong monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.